Boeree Martin J
Radboud University Nijmegen Medical Centre, University Centre for Chronic Disease Dekkerswald, Nijmegen, the Netherlands.
Recent Pat Antiinfect Drug Discov. 2011 May;6(2):99-103. doi: 10.2174/157489111796064533.
Current evidence shows that thioridazine (THZ) is ready for global clinical evaluation, while some of its derivatives and other efflux pump inhibitors reach the end stage of preclinical evaluation. In this paper, a clinical trial plan is described that investigates the antituberculosis potency, the safety profile and the role of THZ and/or its derivatives in the treatment of TB in humans, both in patients infected with drug sensitive strains as in patients infected with multi or extensive drug resistant strains of Mycobacterium tuberculosis and some of the patents related to thioridazine are also discussed.
目前的证据表明，硫利达嗪（THZ）已准备好进行全球临床评估，而其一些衍生物和其他外排泵抑制剂已进入临床前评估的最后阶段。本文描述了一项临床试验计划，该计划研究了THZ及其衍生物在治疗人类结核病中的抗结核效力、安全性概况及作用，受试对象包括感染结核分枝杆菌药物敏感菌株的患者以及感染多药耐药或广泛耐药菌株的患者，同时还讨论了一些与硫利达嗪相关的专利。
